NSTI Nanotech 2009

Targeted Nanoparticles for Cancer Therapy

Ananth Annapragada

Ananth Annapragada

Associate Professor of Health Information Sciences
University of Texas Health Science Center at Houston


  • Post Doctoral Associate 1991 Massachusetts Institute of Technology
  • Post Doctoral Associate 1989 the University of Minnesota Center for Interfacial Engineering
  • PhD 1989 University of Michigan
  • B.Tech 1984 A.C. College of Technology
Research Areas
  • Drug and Contrast Delivery
  • Computational Biomedicine
  • Organ and Organism level simulations

Ananth Annapragada is an Associate Professor in the School of Health Information Sciences at the University of Texas, Health Sciences Center at Houston. He holds additional positions at the Graduate School of Biomedical Sciences, the Keck Institute for Computational and Structural Biology, The University of Houston, Rice University and the University of Texas at Austin. He joined UT in August 2003, after 3 years at the Cleveland Clinic/Cleveland State University Program in Biomedical Engineerng, where he was Associate Professor and Program Director.

Ananth received his Ph.D. in Chemical Engineering from The University of Michigan in 1989. After Post-Doctoral Fellowships at the University of Minnesota and MIT, he joined Abbott Laboratories as a Research Scientist in 1991. In 1996, he joined SEQUUS Pharmaceuticals, Menlo Park, CA. He stayed with SEQUUS through its merger with ALZA, and when ALZA was acquired by Johnson and Johnson, he left for his first Academic position in Cleveland in 2000. In 2003, he moved to Texas, and his current position.

Ananth directs the Laboratory for Computational Biology and Delivery Systems (LCBDS) at UT. His research interests are in drug and contrast agent delivery, particularly physical and receptor targeting processes.

Ananth is a co-founder of a biotech company based on research originating in his laboratory. Marval Therapeutics Inc. was founded in 2002, and progressed via grant funding from the State of Ohio and the SBIR program. In 2007, it was merged with Marval Biosciences Inc. as part of the closing of it’s A-round financing. Marval focuses on a liposomal nanoparticle based contrast agent for CT. For further details on Marval, please contact it’s CEO, Russ Lebovitz, M.D., Ph.D, at rlebovitz@suma.com

Speaking in the symposiums on Cancer Nanotechnology, Drug Delivery, and Nano Medicine

View Confimed Speakers

← Back to Conferences & Symposia

Program | Tracks | Symposia | Workshops | Exhibitor | Press |
Venue | News | Subscribe | Contact | Site Map
© Copyright 2008 Nano Science and Technology Institute. All Rights Reserved.